2022 BDO Life Sciences CDO Outlook Survey

By now, it’s clear: the alterations COVID-19 made to the life sciences landscape aren’t going away.

Fortunately, some of those changes are largely positive: developments made during the pandemic have given rise to new investment opportunities and advanced drug development techniques.

Now, the industry is facing a new world: one where partnerships are preferred, technology is the ticket to de-risking drug development, and supply chain disruptions could threaten the very lifeblood of life sciences.

The 2022 BDO Life Sciences CFO Outlook Survey polls life sciences industry CFOs to understand their plans to navigate this new world — and how they will shape the future of the industry.

Dive into the survey findings to explore the challenges and opportunities facing life sciences in 2022

"The future of life sciences is determined by the choices we make today. Our survey showed that life sciences companies are both taking risks to foster scientific advancement and building more resilience and safety into their businesses and networks. The result? We’re going to see leaps in the life sciences industry leading to better products for patients and a brighter future for the world."

Principal and National Co-Leader, BDO Life Sciences, BioProcess Technology Group


The 2022 BDO Life Sciences CFO Outlook Survey polled 100 life sciences industry CFOs with revenues ranging from $100 million to $3 billion in October 2021. The survey was conducted by Rabin Research Company, an independent marketing research firm, using Op4G’s panel of executives.

Annual Revenue

9% $2B-$3B+

18% $1B-$2B

14% $751M-$999M

13% $501M-$700M

8% $251M-$500M

38% $100M-$250M

Regional Operations For U.S.-Based Companies

63% U.S. only

28% Canada

22% Europe

21% Latin/South America

19% Asia-Pacific

4% Africa


50% Private

50% Public

Types of Life Sciences Organization

20% Biopharma / Pharma

20% Biotech

20% Medtech

20% Medical devices

20% Drug manufacturers / supplies